37 Synovitis is dominated by shared T-cell clones References 1 Bykerk V. 2009; Unmet needs in rheumatoid arthritis. J Rheumatol Suppl. 36(Suppl 82):42–6. 2 Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, et al. 2014; Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 506(7488):376–81. 3 Kruglyak L. 2008; The road to genome-wide association studies. Nat Rev Genet. 9(4):314–8. 4 Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. 2009; Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 106(23):9362–7. 5 Hu X, Kim H, Stahl E, Plenge R, Daly M, Raychaudhuri S. 2011; Integrating autoimmune risk loci with gene-expression data identifies specific pathogenic immune cell subsets. Am J Hum Genet. 89(4):496–506. 6 Yarwood A, Han B, Raychaudhuri S, Bowes J, Lunt M, Pappas DA, Kremer J, Greenberg JD, Plenge R, Rheumatoid Arthritis Consortium International (RACI), Worthington J, Barton A, Eyre S. 2015; A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis. 74(1):170–6. 7 Kremer JM, Westhovens R, Leon M, Giorgio E Di, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker J-C, Hagerty DT, Moreland LW. 2003; Treatment of rheumatoid arthritis by elective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 349(20):1907–15. 8 de Hair MJH, van de Sande MGH, Ramwadhdoebe TH, Hansson M, Landewé R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, Gerlag DM, van Baarsen LGM, Tak PP. 2014; Features of the synovium of individuals at risk of developing rheumatoid arthritis implications for understanding preclinical rheumatoid arthritis: Implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 66(3):513–22. 9 Klarenbeek PL, de Hair MJH, Doorenspleet ME, van Schaik BDC, Esveldt REE, van de Sande MGH, Cantaert T, Gerlag DM, Baeten D, van Kampen AHC, Baas F, Tak PP, de Vries N. 2012; Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis. 71(6):1088–93. 10 Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. 2004; Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 350(25):2572–81. 11 van Zeijl MCT, van den Eertwegh AJ, Haanen JB, Wouters MWJM. 2017; (Neo)adjuvant systemic therapy for melanoma. Eur J Surg Oncol. 43(3):534–43. 12 Le Mercier I, Lines JL, Noelle RJ. 2015; Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol. 6(Aug):1–15. 13 Cantaert T, Brouard S. 2009; Alterations of the synovial T cell repertoire in anti–citrullinated protein antibody–positive rheumatoid arthritis. Arthritis Rheum. 60(7):1944–56. 14 Schmidt D, Martens PB, Weyand CM, Goronzy JJ. 1996; The repertoire of CD4+ CD28- T cells in rheumatoid arthritis. Mol Med. 2(5):608–18. 2
RkJQdWJsaXNoZXIy MTk4NDMw